GlassScriptPhysician profile
Meena Seenivasan
NPI 1255308185
$5,718.72
in general payments reported to CMS, 2019-2025
18 companies · $975 in 2025
The $975 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $511 · 2021: $856 · 2022: $662 · 2023: $1,080 · 2024: $1,127 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,181.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,170.46 | 2019-2025 | Descovy, Biktarvy |
| Viiv Healthcare Company | $890.89 | 2019-2025 | Dovato, Apretude, Cabenuva |
| La Jolla Pharmaceutical Company | $763.07 | 2020-2025 | Xacduro, Zevtera |
| Merck Sharp & Dohme LLC | $685.31 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Abbvie INC. | $456.92 | 2021-2025 | Teflaro, Mavyret, Dalvance |
| Insmed, INC. | $365.20 | 2019-2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $335.07 | 2020-2025 | Nuzyra |
| Shionogi INC | $318.16 | 2024-2025 | Fetroja |
| Melinta Therapeutics, LLC | $294.84 | 2019-2023 | Rezzayo, Kimyrsa, Vabomere |
| Organogenesis INC. | $119.80 | 2024 | |
| Theratechnologies INC. | $87.16 | 2019-2025 | Egrifta, Trogarzo |
| Cumberland Pharmaceuticals, INC. | $80.95 | 2024-2025 | Vibativ |
| Ferring Pharmaceuticals INC. | $46.01 | 2023-2024 | Rebyota |
| Allergan, INC. | $28.06 | 2020 | |
| Janssen Biotech, INC. | $26.70 | 2019-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.53 | 2025 | |
| Aimmune Therapeutics, INC. | $16.75 | 2024 | |
| Bavarian Nordic A/S | $15.84 | 2025 | Vivotif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meena Seenivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.